US EditionSibeprenlimab's priority review highlights potential to differentiate in IgAN space
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Sibeprenlimab's priority review highlights potential to differentiate in IgAN space - Express Pharma
Otsuka Pharmaceutical recently announced that the FDA has accepted for review the Biologics License Application (BLA) for sibeprenlimab, which acts as A Proliferation Inducing Ligand (APRIL) inhibitor in development for immunoglobulin A (IgA) nephropathy (IgAN). This followed sibeprenlimab’s 2024 FDA breakthrough designation for the same indication. The BLA was supported by the Phase III VISIONARY trial data. If approved, sibeprenlimab could pro…
Sibeprenlimab's priority review highlights potential to differentiate in IgAN space, says GlobalData - GlobalData
Otsuka Pharmaceutical recently announced that the FDA has accepted for review the Biologics License Application (BLA) for sibeprenlimab, which acts as A Proliferation Inducing Ligand (APRIL) inhibitor in development for immunoglobulin A (IgA) nephropathy (IgAN). This followed sibeprenlimab’s 2024 FDA breakthrough designation for the same indication. The BLA was supported by the Phase III VISIONARY trial data. If approved, sibeprenlimab could pro…
Sibeprenlimab's priority review highlights potential to differentiate in IgAN space
Sibeprenlimab acts as an a proliferation-inducing ligand (APRIL) inhibitor in development for immunoglobulin A (IgA) nephropathy (IgAN).The post Sibeprenlimab’s priority review highlights potential to differentiate in IgAN space appeared first on Clinical Trials Arena.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
